These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 20523271)

  • 1. Prowess-shock trial: a protocol overview and perspectives.
    Silva E; de Figueiredo LF; Colombari F
    Shock; 2010 Sep; 34 Suppl 1():48-53. PubMed ID: 20523271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corticosteroids and human recombinant activated protein C for septic shock.
    Colin G; Annane D
    Clin Chest Med; 2008 Dec; 29(4):705-12, x. PubMed ID: 18954704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.
    Laterre PF; Nelson DR; Macias W; Abraham E; Sashegyi A; Williams MD; Levy M; Levi M; Utterback B; Vincent JL
    J Crit Care; 2007 Jun; 22(2):142-52. PubMed ID: 17548026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.
    Barie PS; Hydo LJ; Shou J; Eachempati SR
    Surg Infect (Larchmt); 2006; 7 Suppl 2():S77-80. PubMed ID: 16895513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.
    Laterre PF; Macias WL; Janes J; Williams MD; Nelson DR; Girbes AR; Dhainaut JF; Abraham E
    Crit Care; 2008; 12(5):R117. PubMed ID: 18786266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study.
    Laterre PF; Garber G; Levy H; Wunderink R; Kinasewitz GT; Sollet JP; Maki DG; Bates B; Yan SC; Dhainaut JF;
    Crit Care Med; 2005 May; 33(5):952-61. PubMed ID: 15891319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, observational study of Xigris Use in the United States (XEUS).
    Steingrub JS; Cheatham ML; Woodward B; Wang HT; Effron MB;
    J Crit Care; 2010 Dec; 25(4):660.e9-16. PubMed ID: 20435433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [PROWESS, ENHANCE and ADDRESS: clinical implications for the treatment with drotrecogin alfa (activated)].
    Cobas Meyer M; Langenfeld H; Rossaint R; Sablotzki A
    Anaesthesist; 2006 Jun; 55 Suppl 1():16-23. PubMed ID: 16680442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated protein C and septic shock: a propensity-matched cohort study*.
    Rimmer E; Kumar A; Doucette S; Marshall J; Dial S; Gurka D; Dellinger RP; Sharma S; Penner C; Kramer A; Wood K; Ronald J; Kumar A; Turgeon AF; Houston DS; Zarychanski R;
    Crit Care Med; 2012 Nov; 40(11):2974-81. PubMed ID: 22932397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
    Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
    Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drotrecogin alfa (activated) in adults with septic shock.
    Ranieri VM; Thompson BT; Barie PS; Dhainaut JF; Douglas IS; Finfer S; Gårdlund B; Marshall JC; Rhodes A; Artigas A; Payen D; Tenhunen J; Al-Khalidi HR; Thompson V; Janes J; Macias WL; Vangerow B; Williams MD;
    N Engl J Med; 2012 May; 366(22):2055-64. PubMed ID: 22616830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.
    Finfer S; Ranieri VM; Thompson BT; Barie PS; Dhainaut JF; Douglas IS; Gårdlund B; Marshall JC; Rhodes A
    Intensive Care Med; 2008 Nov; 34(11):1935-47. PubMed ID: 18839141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editors' comments on a new trial of activated protein C for persistent septic shock.
    Mancebo J; Antonelli M
    Intensive Care Med; 2008 Nov; 34(11):1948-9. PubMed ID: 18839138
    [No Abstract]   [Full Text] [Related]  

  • 15. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
    Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Science, medicine and industry: are we getting out of the black hole in sepsis research?
    Suter PM; Takala J
    Intensive Care Med; 2008 Nov; 34(11):1950-4. PubMed ID: 18839139
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
    Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR;
    Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once is not enough: clinical trials in sepsis.
    Sweeney DA; Danner RL; Eichacker PQ; Natanson C
    Intensive Care Med; 2008 Nov; 34(11):1955-60. PubMed ID: 18839140
    [No Abstract]   [Full Text] [Related]  

  • 19. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
    Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
    JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of drotrecogin alpha use in a Belgian university hospital.
    Spriet I; Meersseman W; Wilmer A; Meyfroidt G; Casteels M; Willems L
    Pharm World Sci; 2006 Oct; 28(5):290-5. PubMed ID: 17111246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.